CIK 0001374690 · Non-accelerated filer<br>Smaller reporting company
Larimar Therapeutics, Inc.
Sign in to watch- Ticker
- LRMR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 203857670
- Phone
- 844-511-9056
- Business address
- THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA, 19004
- Former names
- ZAFGEN, INC., ZAFGEN INC
- Open-market buys, last 90 days
- $382,086
- in 7 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$382,086. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-01-17 | Shankar Gopi Chief Development Officer | Grant or award · Stock Option (Right to Buy) | +135,000 | 135,000 | ||
| 2024-01-17 | Celano Michael Chief Financial Officer | Grant or award | +31,250 | 143,996 | ||
| 2024-01-17 | Celano Michael Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +187,500 | 187,500 | ||
| 2024-01-17 | Clayton Russell Chief Medical Officer | Grant or award | +22,500 | 22,500 | ||
| 2024-01-17 | Clayton Russell Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +135,000 | 135,000 | ||
| 2024-01-17 | BEN-MAIMON CAROLE President and CEO | Grant or award | +66,125 | 332,954 | ||
| 2024-01-17 | BEN-MAIMON CAROLE President and CEO | Grant or award · Stock Option (Right to Buy) | +396,750 | 396,750 | ||
| 2023-12-07 | Shankar Gopi Chief Development Officer | Purchase | +5,000 | $3.73 | $19K | 5,000 |
| 2023-10-03 | SHERMAN JEFFREY W Director | Grant or award · Stock Option (Right to Buy) | +16,600 | 16,600 | ||
| 2023-07-17 | Clayton Russell Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +180,000 | 180,000 | ||
| 2023-05-17 | Celano Michael Chief Financial Officer | Purchase | +5,000 | $3.73 | $19K | 112,746 |
| 2023-05-17 | BEN-MAIMON CAROLE President and CEO | Purchase | +5,000 | $3.71 | $19K | 266,829 |
| 2023-05-17 | Truitt Joseph Director | Purchase | +2,750 | $3.73 | $10K | 2,750 |
| 2023-05-09 | Flynn James E Director | Grant or award · Stock Option (Right to Buy) | +8,300 | 8,300 | ||
| 2023-05-09 | Truitt Joseph Director | Grant or award · Stock Option (Right to Buy) | +8,300 | 8,300 | ||
| 2023-05-09 | Hamilton Thomas Edward Director | Grant or award · Stock Option (Right to Buy) | +8,300 | 8,300 | ||
| 2023-05-09 | LEFF JONATHAN S Director | Grant or award · Stock Option (Right to Buy) | +8,300 | 8,300 | ||
| 2023-05-09 | THOMAS FRANK E Director | Grant or award · Stock Option (Right to Buy) | +8,300 | 8,300 | ||
| 2023-02-07 | Shankar Gopi Chief Development Officer | Grant or award · Stock Option (Right to Buy) | +180,000 | 180,000 | ||
| 2023-01-31 | Celano Michael Chief Financial Officer | Grant or award | +76,000 | 107,746 |
Page 4 of 7 · 136 trades